Trial Profile
An Open Label, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of APL-2 as an Add-On to Standard of Care in Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 Jan 2021
Price :
$35
*
At a glance
- Drugs Pegcetacoplan (Primary)
- Indications Paroxysmal nocturnal haemoglobinuria
- Focus Adverse reactions; Pharmacokinetics; Proof of concept
- Acronyms PHAROAH
- Sponsors Apellis Pharmaceuticals
- 05 Dec 2019 Status changed from active, no longer recruiting to completed.
- 13 Nov 2018 According to an Apellis Pharmaceuticals media release, the company expects to provide an update on the trial at the 2018 ASH conference in December.
- 04 Sep 2018 Results published in the Apellis Pharmaceuticals Media Release